AstraZeneca CICC Medical Industry Fund

The AstraZeneca CICC Medical Industry Fund shows up in elsewhere's corpus purely through its deal activity — the material doesn't cover its founding details or structure, so what can be said is what it does. It invests in Chinese biotech across modalities: it co-led Axbio's nearly $100M Series B in mid-2022 alongside Yunfeng Capital, per 5Y Capital ; joined Gaorong-led rounds in Kailan Pharma (cholesterol metabolism drugs) in 2023 and topped up in the 2025 A+ round ; and most recently led YolTech Therapeutics' RMB 300M+ Series B in September 2025, backing the in-vivo gene editing company founded in 2021, per Unity Ventures . The pattern across these deals is a healthcare-dedicated fund active from Series A through B, willing to both lead and follow alongside dollar and RMB VCs.